Re: The Life Insurance Issue

[Guest guest]

A big

> challenge likely is that the medications that are now considered

front-line

> treatment haven't been shown yet to extend survival (or is that data

now

> coming in?).

>******************************************

I would say that there is clear evidence to show that Gleevec is

extending survival for CMLer's. Just look at the 5 year data for

Gleevec users as compared to people who have had a BMT.

According to

http://www.marrow.org/PHYSICIAN/URD_Search_and_Tx/Comparing_URD_Sibling_

Donor_Tx/index.html

The five year survival rate for people who had a BMT for CML is 53%.

Now compare that with the recent 5 year statistics for Gleevec users

(the IRIS trial)and there's really no comparison at all. 5 year

survival rates for Gleevec users is over 90%. Looks pretty clear to

me

Tracey